DiaMedica Therapeutics 주식 (NASDAQ: DMAC)

에 대한 최신 뉴스 DiaMedica Therapeutics (NASDAQ:DMAC) 주식

DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics Inc

<p>Shares of <strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) soared 8.1% to $208.68 Monday afternoon after the U.S. and China <a href="https://www.benzinga.com/government/regulations/25/05/45355655/magnificent-seven-gain-700b-after-us-china-slash-tariffs-gold-crashes-whats-driving-markets-monday">announced</a> a temporary easing of tariffs, marking a significant step toward de-escalating long-standing trade tensions. The move lifted investor sentiment across sectors and boosted shares of companies heavily reliant on global supply chains.</p>
<p><strong>What To Know:</strong> Amazon stands to benefit directly from the tariff reprieve. As one of the world's largest e-commerce and cloud services companies, Amazon is deeply integrated with global manufacturing, particularly in <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs">China</a>.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/25/05/45355529/needham-says-draftkings-dkng-q1-handle-should-calm-fears">Needham Says DraftKings Q1 Handle Should &#8216;Calm Fears&#8217;</a></strong></p>
<p>Many of the products sold on Amazon's marketplace—including electronics, consumer goods and private-label brands—are sourced or assembled in Chinese factories. Lower import tariffs reduce the company's cost of goods sold, improving profit margins across its retail segment.</p>
<p>Additionally, Amazon Web Services could gain ground in international markets amid improving geopolitical relations, as fewer regulatory frictions may ease data localization pressures and expand enterprise cloud adoption in Asia.</p>
<p>Beyond its direct exposure, Amazon's stock rise also reflects <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">broader bullish sentiment</a> in tech during Monday&#8217;s session. With global supply chains potentially stabilizing and trade risk easing, investors could be pricing in stronger revenue growth, improved logistics and greater consumer confidence heading into the second half of the year.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/25/05/45354368/why-marvell-technology-mrvl-stock-is-soaring-today">Why Marvell Technology Stock Is Soaring Today</a></strong></p>
<h2 class="wp-block-heading">How To Buy AMZN Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Amazon&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMZN has a 52-week high of $242.52 and a 52-week low of $151.61.</p>


News

AMZN

Amazon (AMZN) Stock Soars 8% Monday: What's Going On?

<p><strong>Goldman Sachs </strong>analyst Michael Ng <a target="_blank" href="https://www.benzinga.com/quote/PARA/analyst-ratings" rel="noreferrer noopener">remained Not Rated</a> on <strong>Paramount Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) on Friday.</p>
<p>Revenue of $7.19 billion beat Ng and consensus estimate of $7.04 billion and $7.1 billion.</p>
<p>Adjusted OIBDA of $688 million beat $652 million and $666 million Ng and consensus estimate driven by a broad-based beat across DTC, TV Media, and Film.</p>
<p><em><strong>Also Read: <a href="https://www.benzinga.com/25/03/44120055/paramount-gains-engagement-but-tv-and-film-struggles-lead-to-analyst-outlook-revision" target="_blank" rel="noreferrer noopener">Paramount Faces PayTV Declines, But Streaming And Licensing Gains Prompt Analyst Estimate Revisions</a></strong></em></p>
<p>TV Media advertising was flat on an underlying basis on Super Bowl comps, helped by strong sports programming like March Madness and the NFL Playoffs.</p>
<p>Like <strong>Warner Bros. Discovery, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), advertising outperformed, and there has been limited discernible impact from macro uncertainty, Ng noted.</p>
<p>DTC advertising declined 1% on an underlying basis on Super Bowl comps, which should continue throughout 2025, driven by growing industry AVOD supply (e.g., <strong>Amazon.Com Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>)) as per the analyst.</p>
<p>The analyst remarked that Paramount expects the proposed Skydance acquisition to close in the first half of 2025. Free cash flow of $123 million beat the analyst&#8217;s estimate of $69 million and $13 million.</p>
<p>DTC revenue of $2.04 billion missed the consensus estimates of $2.1 billion and $2.09 billion, with OIBDA of $(109) million above the analyst and the consensus estimates of $(128) million and $(153) million. Paramount+ subscribers increased to 79.0 million (versus Ng&#8217;s estimate of 78.6 million), and global Paramount+ revenue grew 16% (versus Ng&#8217;s estimate of +12%).</p>
<p>TV Media revenue of $4.54 billion beat Ng and consensus estimate of $4.39 billion and $4.43 billion, with OIBDA of $922 million beating Ng estimate of $904 million but missing consensus of $951 million.</p>
<p>Filmed Entertainment revenue of $627 million was above Ng and consensus estimate of $575 million and $610 million, with OIBDA of $20 million beating Ng and consensus estimate of $13 million and $17 million.</p>
<p>Paramount introduced second-quarter guidance including subscriber decline at Paramount+ due to content seasonality and termination of an international bundle, Paramount+ ARPU growth to accelerate off first-quarter 2025, TV Media affiliate revenue decline rates to see similar underlying trends versus first-quarter 2025, TV Media advertising to see similar underlying trends versus first-quarter 2025 in digital while deceleration in linear, OIBDA loss in Studios driven by costs associated with the release of Mission Impossible &#8211; The Final Reckoning and free cash flow to Mirror last year.</p>
<p>Paramount reiterated 2025 guidance, including OIBDA, which will modestly decline, including impacts from the Super Bowl, free cash flow, which will increase, including 2024 Super Bowl and political advertising impacts, and domestic profitability for Paramount+.</p>
<p>The analyst projects fiscal 2025 revenue of $28.7 billion and adjusted EPS of $0.81.</p>
<p><strong>Price Action:&nbsp;</strong>PARA stock is up 0.50% by $12.00 at last check Monday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener"><em>Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</em></a></strong></li>
</ul>


Analyst Color

Entertainment

Price Target

Analyst Ratings

Tech

Media

Trading Ideas

PARA

PARAA

Paramount's Super Bowl Boost And Studio Strength Help Offset Streaming Miss: Analyst

<p>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Humacyte will report an <strong>earnings per share</strong> (EPS) of $-0.21.</p>
<p>The market awaits Humacyte's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Humacyte's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.25</td>
<td>-0.25</td>
<td>-0.24</td>
<td>-0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.33</td>
<td>-0.27</td>
<td>-0.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>10.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747077165_0.png" alt="eps graph" /></p>
<h3>Market Performance of Humacyte's Stock</h3>
<p>Shares of Humacyte were trading at $1.19 as of May 09. Over the last 52-week period, shares are down 79.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HUMA/earnings"><strong>To track all earnings releases for Humacyte visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

HUMA

Exploring Humacyte's Earnings Expectations

<p>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Cellectar Biosciences will report an <strong>earnings per share</strong> (EPS) of $-0.16.</p>
<p>Anticipation surrounds Cellectar Biosciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.34, which was followed by a 5.34% increase in the share price the next day.</p>
<p>Here's a look at Cellectar Biosciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.35</td>
<td>-0.37</td>
<td>-1</td>
<td>-0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.01</td>
<td>-0.40</td>
<td>-0.18</td>
<td>-0.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-9.0%</td>
<td>0.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747077057_0.png" alt="eps graph" /></p>
<h3>Market Performance of Cellectar Biosciences's Stock</h3>
<p>Shares of Cellectar Biosciences were trading at $0.2474 as of May 09. Over the last 52-week period, shares are down 91.9%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CLRB/earnings"><strong>To track all earnings releases for Cellectar Biosciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CLRB

Insights Ahead: Cellectar Biosciences's Quarterly Earnings

<p><a href="https://www.biorxiv.org/content/10.1101/2025.05.09.652772v1">https://www.biorxiv.org/content/10.1101/2025.05.09.652772v1</a></p>


Biotech

General

AEMD

Watching Aethlon Medical; Traders Circulate Article From bioRxiv: "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin (Aethlon Medical's Hemopurifier)"

<p>Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Intellinetics to report an <strong>earnings per share</strong> (EPS) of $-0.07.</p>
<p>The market awaits Intellinetics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 8.11% increase in the share price on the subsequent day.</p>
<p>Here's a look at Intellinetics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>0.01</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.01</td>
<td>-0.09</td>
<td>0.02</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-13.0%</td>
<td>-7.000000000000001%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076994_0.png" alt="eps graph" /></p>
<h3>Intellinetics Share Price Analysis</h3>
<p>Shares of Intellinetics were trading at $13.4994 as of May 09. Over the last 52-week period, shares are up 51.52%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/INLX/earnings"><strong>To track all earnings releases for Intellinetics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


INLX

Uncovering Potential: Intellinetics's Earnings Preview

<p>Artificial intelligence has <a href="https://www.benzinga.com/tech/25/05/45338301/zuckerberg-foresees-tech-industry-revolution-with-ai-an-ai-that-can-effectively-be-a-sort-of-midlevel-engineer">captured the imagination</a> of virtually every company in the tech world as the technology rapidly becomes more powerful. <strong>Perplexity</strong>, an AI startup and a potential threat to <strong>Alphabet Inc</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) <strong>Google</strong>, was valued at $14 billion in its latest funding round.</p>
<p><strong>What Happened:</strong> The company is in advanced talks with venture-capital firm Accel for a $500 million funding round that places the San Francisco-based company <a href="https://www.benzinga.com/news/25/04/44865115/figure-ai-shakes-silicon-valley-with-39-5b-valuation-200000-robots-promised-by-2029-beating-out-spacex-and-openai">among the most valuable</a> AI startups, <a href="https://www.wsj.com/tech/ai-startup-perplexitys-valuation-surges-to-14-billion-in-fresh-funding-round-26124482?msockid=21c662101c496b42343370ae1de86aaa">according</a> to The Wall Street Journal.</p>
<p>The company was valued at $9 billion in November 2024, representing an over 50% increase in valuation in the past six months. However, the $14 billion figure falls under the start-up&#8217;s desired $18 billion valuation in March, <a href="https://x.com/haydenfield/status/1921981248857084190">according</a> to CNBC&#8217;s Hayden Field.</p>
<p><strong>Jeff Bezos</strong> and Japan&#8217;s <strong>SoftBank Group</strong> are among Perplexity&#8217;s past investors, according to Reuters.</p>
<p><strong>Why it Matters:</strong> Perplexity is a search engine that delivers answers to any question by searching the web and compiling information from multiple sources. Unlike traditional search engines, it provides inline citations, allowing users to verify facts easily. Despite some enthusiasm, Perplexity faces many hurdles, including high infrastructure costs and concerns over the legality of its content.</p>
<p>Several reports have likened Perplexity to a <a href="https://www.benzinga.com/25/05/45311557/gene-munster-warns-googles-search-grip-is-slipping-as-chatgpt-alters-user-behavior-doj-turns-up-the-heat">rival of Google</a> as the latter experiences <a href="https://www.benzinga.com/25/05/45339953/apple-exec-says-iphone-users-are-ditching-google-search-now-chamath-palihaptiya-urges-the-tech-giant-to-stop-waiting-for-data-and-start-fighting-models-like-chatgpt">stagnant search query</a> growth. While the Mountain View, California-based company still maintains a dominant industry position with its search business, its market share sits at its lowest in decades.</p>
<p><strong>OpenAI</strong> was <a href="https://www.benzinga.com/25/04/44580172/openai-finalizes-historic-40-billion-funding-round-valuing-company-at-300-billion-with-backing-from-softbank-and-microsoft">valued at $300 billion</a> in an April funding round. <strong>Elon Musk</strong>&#8216;s <strong>xAI</strong>, another tech industry newcomer, was <a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion">valued at $80 billion</a> in March.</p>
<p><strong>Also Read:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/government/regulations/25/05/45355655/magnificent-seven-gain-700b-after-us-china-slash-tariffs-gold-crashes-whats-driving-markets-monday">Magnificent Seven Gain $700B After US-China Slash Tariffs, Gold Crashes: What&#8217;s Driving Markets Monday?</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence via Midjourney.</em></p>


Financing

GOOG

GOOGL

Perplexity's $14 Billion Valuation Ignites Google Search Engine Shakeup

<p>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Quoin Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-4.20.</p>
<p>Anticipation surrounds Quoin Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 3.17% increase in the share price the next day.</p>
<p>Here's a look at Quoin Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.43</td>
<td>-0.49</td>
<td>-0.61</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.35</td>
<td>-0.47</td>
<td>-0.39</td>
<td>-1.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076929_0.png" alt="eps graph" /></p>
<h3>Tracking Quoin Pharmaceuticals's Stock Performance</h3>
<p>Shares of Quoin Pharmaceuticals were trading at $6.19 as of May 09. Over the last 52-week period, shares are down 76.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/QNRX/earnings"><strong>To track all earnings releases for Quoin Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QNRX

A Peek at Quoin Pharmaceuticals's Future Earnings

<p>Last Wednesday, <strong>NeuroSense Therapeutics Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) said it scaled up its production of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">PrimeC to a commercial scale</a>.</p>
<p>PrimeC, NeuroSense&#8217;s lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.</p>
<p>NeuroSense said it bolstered its supply chain by implementing comprehensive Chemistry, Manufacturing, and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45251140/neurosense-therapeutics-announces-successful-completion-of-commercial-manufacturing-scale-up-for-p" rel="noreferrer noopener">Controls (CMC) enhancements</a>.</p>
<p>Additionally, the company partnered with a global contract development and manufacturing organization (CDMO) that currently manufactures PrimeC clinical batches and will support its future commercial supply.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41571215/exclusive-nano-cap-neurosense-schedules-fda-meeting-to-advance-lead-program-and-marketing-applicatio" rel="noreferrer noopener">EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission</a></em></strong></p>
<p>Stability data support a shelf life of at least&nbsp;36 months at room temperature, and formulation IP granted in 2023 provides protection through 2042.</p>
<p>NeuroSense is working to advance discussions with Health Canada to pursue early market entry through the Notice of Compliance with Conditions (NOC/c) pathway.</p>
<p>Commercial forecasts suggest a potential peak annual revenue of $100–150 million in&nbsp;Canada.</p>
<p><strong>D. Boral Capital</strong> initiated coverage on NeuroSense on Monday with a Buy rating and <a href="https://www.benzinga.com/quote/NRSN/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $14</a>.</p>
<p>Analyst <strong>Jason Kolbert</strong> says, &#8220;The mechanistic rationale is supported by both preclinical and translational research, positioning PrimeC as a multimodal therapy in a field still dominated by marginally effective monotherapies.&#8221;</p>
<p>D. Boral writes that the ongoing Phase 2b PARADIGM trial is designed to provide further validation and is expected to report topline results in the second half of 2025.</p>
<p>In April, NeuroSense shared new findings from its Phase&nbsp;2b&nbsp;PARADIGM clinical trial. The data highlights the impact of PrimeC on microRNA (miRNA) modulation, representing a significant development in understanding how the therapy may slow disease progression.</p>
<p>It reveals the consistent effect of PrimeC on altering the expression of miRNAs associated with ALS, aligning with the previously reported clinical benefits, including a 33% reduction in disease progression and a 58% improvement in survival rates observed with PrimeC treatment.</p>
<p>The analyst notes that NeuroSense is expanding its platform into Alzheimer&#8217;s and Parkinson&#8217;s disease, leveraging the same pathophysiologic targets with modified drug combinations. This modular approach could significantly broaden the company&#8217;s addressable market while maintaining development efficiency.</p>
<p>&#8220;We believe NeuroSense is at an inflection point where clinical proof-of-concept data, coupled with upcoming catalysts, could drive substantial value creation,&#8221; Kolbert adds.</p>
<p>In August 2024, NeuroSense Therapeutics said it was in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40596888/exclusive-neurosense-therapeutics-in-advanced-talks-with-several-multi-billion-dollar-pharma-comp" rel="noreferrer noopener">commercialize PrimeC for&nbsp;ALS</a>.</p>
<p><strong>Price Action: </strong>NRSN stock is up 6.34% at $1.11 at the last check on Monday.</p>
<p><strong><em>Read Next:</em></strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a></em></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Health Care

Initiation

Movers

NRSN

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

<p>Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Gevo to report an <strong>earnings per share</strong> (EPS) of $-0.08.</p>
<p>Investors in Gevo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 9.92% drop in the share price the following trading session.</p>

<p><img src="https://www.benzinga.com/files/images/story/2025/1747076657_0.png" alt="eps graph" /></p>
<h3>Performance of Gevo Shares</h3>
<p>Shares of Gevo were trading at $1.16 as of May 09. Over the last 52-week period, shares are up 61.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Gevo</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gevo.</p>
<p>A total of 3 analyst ratings have been received for Gevo, with the consensus rating being Buy. The average one-year price target stands at $9.72, suggesting a potential 737.93% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Green Plains, Clean Energy Fuels and REX American Resources, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Green Plains, with an average 1-year price target of $7.3, suggesting a potential 529.31% upside.</li>
<li>Analysts currently favor an Buy trajectory for Clean Energy Fuels, with an average 1-year price target of $4.33, suggesting a potential 273.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for REX American Resources, with an average 1-year price target of $50.0, suggesting a potential 4210.34% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Green Plains, Clean Energy Fuels and REX American Resources, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gevo</td>
<td>Buy</td>
<td>30.32%</td>
<td>$2.25M</td>
<td>-3.54%</td>
</tr>
<tr>
<td>Green Plains</td>
<td>Neutral</td>
<td>-18.02%</td>
<td>$6.15M</td>
<td>-6.14%</td>
</tr>
<tr>
<td>Clean Energy Fuels</td>
<td>Buy</td>
<td>2.31%</td>
<td>$23.57M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>REX American Resources</td>
<td>Buy</td>
<td>-15.66%</td>
<td>$17.57M</td>
<td>1.97%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Gevo is positioned at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Gevo's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its equity holders.</p>
<h3>Get to Know Gevo Better</h3>
<p>Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.</p>
<h3>Financial Insights: Gevo</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Gevo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>30.32%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-308.89%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Gevo's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-3.54%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Gevo's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-2.96%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.14</strong>, Gevo adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/GEVO/earnings"><strong>To track all earnings releases for Gevo visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GEVO

Insights Ahead: Gevo's Quarterly Earnings

<p>MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ:&nbsp;MLGO), they announced today their research on quantum visual computing, exploring the integration of quantum computing with classical convolutional neural networks. They are developing a Quantum Convolutional Neural Network (QCNN) architecture to enhance the performance of traditional computer vision tasks using quantum mechanics principles.</p>


MLGO

MicroAlgo Announces Research On Quantum Visual Computing, Exploring Integration Of Quantum Computing With Classical Convolutional Neural Networks

<p><strong>Nutex Health</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Nutex Health will report an <strong>earnings per share</strong> (EPS) of $-0.15. </p>
<p>Nutex Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at Nutex Health's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td>-0.24</td>
<td>-0.02</td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>11.12</td>
<td>-1.72</td>
<td>-0.07</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>52.0%</td>
<td>9.0%</td>
<td>28.000000000000004%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Nutex Health Share Price Analysis</h3>
<p>Shares of Nutex Health were trading at $120.73 as of May 09. Over the last 52-week period, shares are up 1638.17%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Observations about Nutex Health</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Nutex Health.</p>
<p>A total of 2 analyst ratings have been received for Nutex Health, with the consensus rating being Buy. The average one-year price target stands at $87.5, suggesting a potential 27.52% downside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Fulgent Genetics, Talkspace and Castle Biosciences, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Fulgent Genetics, with an average 1-year price target of $21.33, suggesting a potential 82.33% downside.</li>
<li>Analysts currently favor an Buy trajectory for Talkspace, with an average 1-year price target of $5.0, suggesting a potential 95.86% downside.</li>
<li>Analysts currently favor an Buy trajectory for Castle Biosciences, with an average 1-year price target of $36.33, suggesting a potential 69.91% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Fulgent Genetics, Talkspace and Castle Biosciences are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutex Health</td>
<td>Buy</td>
<td>269.77%</td>
<td>$141.63M</td>
<td>59.67%</td>
</tr>
<tr>
<td>Fulgent Genetics</td>
<td>Neutral</td>
<td>13.92%</td>
<td>$28.35M</td>
<td>-1.02%</td>
</tr>
<tr>
<td>Talkspace</td>
<td>Buy</td>
<td>7.11%</td>
<td>$21.53M</td>
<td>0.28%</td>
</tr>
<tr>
<td>Castle Biosciences</td>
<td>Buy</td>
<td>20.57%</td>
<td>$71.61M</td>
<td>-5.77%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nutex Health ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>All You Need to Know About Nutex Health</h3>
<p>Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.</p>
<h3>Financial Insights: Nutex Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Nutex Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>269.77%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Nutex Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.95%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>59.67%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Nutex Health's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>11.28%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.33</strong>, Nutex Health faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/NUTX/earnings"><strong>To track all earnings releases for Nutex Health visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NUTX

Earnings Preview For Nutex Health

<p>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Capricor Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.32.</p>
<p>Capricor Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.15, leading to a 17.51% increase in the share price the following trading session.</p>
<p>Here's a look at Capricor Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.31</td>
<td>-0.36</td>
<td>-0.36</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.38</td>
<td>-0.35</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>18.0%</td>
<td>9.0%</td>
<td>9.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076571_0.png" alt="eps graph" /></p>
<h3>Market Performance of Capricor Therapeutics's Stock</h3>
<p>Shares of Capricor Therapeutics were trading at $6.34 as of May 09. Over the last 52-week period, shares are up 37.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Capricor Therapeutics</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Capricor Therapeutics.</p>
<p>The consensus rating for Capricor Therapeutics is Buy, derived from 4 analyst ratings. An average one-year price target of $65.25 implies a potential 929.18% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Rigel Pharmaceuticals, with an average 1-year price target of $39.75, suggesting a potential 526.97% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 21.14% downside.</li>
<li>Analysts currently favor an Buy trajectory for Abeona Therapeutics, with an average 1-year price target of $16.5, suggesting a potential 160.25% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-29.86%</td>
<td>$71.30M</td>
<td>-6.32%</td>
</tr>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>Buy</td>
<td>80.58%</td>
<td>$48.92M</td>
<td>104.74%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Abeona Therapeutics</td>
<td>Buy</td>
<td>0.00%</td>
<td>$0</td>
<td>-20.70%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Capricor Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it ranks in the middle for Return on Equity, suggesting a moderate level of profitability relative to others.</p>
<h3>Unveiling the Story Behind Capricor Therapeutics</h3>
<p>Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.</p>
<h3>Breaking Down Capricor Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Capricor Therapeutics faced challenges, resulting in a decline of approximately <strong>-7.92%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Capricor Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-63.94%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Capricor Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-6.66%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.4%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Capricor Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/CAPR/earnings"><strong>To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CAPR

A Look Ahead: Capricor Therapeutics's Earnings Forecast

<p>High-rolling investors have positioned themselves bearish on Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in U often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for Unity Software. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 15% bullish and 61% bearish. Among all the options we identified, there was one put, amounting to $160,665, and 12 calls, totaling $633,463.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $26.0 for Unity Software over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Unity Software options trades today is 3609.5 with a total volume of 3,361.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Unity Software's big money trades within a strike price range of $20.0 to $26.0 over the last 30 days.</p>
<h3>Unity Software 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076478_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$6.55</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$26.00</td>
<td>$160.6K</td>
<td>0</td>
<td>251</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.0</td>
<td>$1.88</td>
<td>$2.0</td>
<td>$20.00</td>
<td>$99.6K</td>
<td>2.7K</td>
<td>302</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.01</td>
<td>$1.87</td>
<td>$1.9</td>
<td>$20.00</td>
<td>$95.0K</td>
<td>2.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.01</td>
<td>$1.87</td>
<td>$1.9</td>
<td>$20.00</td>
<td>$95.0K</td>
<td>2.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.25</td>
<td>$2.91</td>
<td>$3.09</td>
<td>$25.00</td>
<td>$77.1K</td>
<td>12.1K</td>
<td>261</td>
</tr>
</tbody>
</table>
</p>
<h3>About Unity Software</h3>
<p>Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.</p>
<p>Following our analysis of the options activities associated with Unity Software, we pivot to a closer look at the company's own performance.</p>
<h3>Unity Software's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,940,477, the price of U is up by 4.82%, reaching $21.55.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>What The Experts Say On Unity Software</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $27.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Unity Software, targeting a price of $25.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Unity Software, which currently sits at a price target of $25.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Unity Software, which currently sits at a price target of $28.<br />
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Unity Software, targeting a price of $30. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Unity Software options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Unity Software's Options: A Look at What the Big Money is Thinking

<p>Financial giants have made a conspicuous bullish move on Pinterest. Our analysis of options history for Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) revealed 32 unusual trades.</p>
<p>Delving into the details, we found 40% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $155,510, and 30 were calls, valued at $1,387,451.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $18.0 to $45.0 for Pinterest during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pinterest's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pinterest's substantial trades, within a strike price spectrum from $18.0 to $45.0 over the preceding 30 days.</p>
<h3>Pinterest 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076473_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$13.25</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$25.00</td>
<td>$150.8K</td>
<td>656</td>
<td align="right">117</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.08</td>
<td>$27.00</td>
<td>$121.5K</td>
<td>1.5K</td>
<td align="right">430</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.45</td>
<td>$12.0</td>
<td>$12.1</td>
<td>$45.00</td>
<td>$121.0K</td>
<td>0</td>
<td align="right">200</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$15.0</td>
<td>$14.65</td>
<td>$14.8</td>
<td>$20.00</td>
<td>$74.0K</td>
<td>137</td>
<td align="right">100</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$4.65</td>
<td>$5.3</td>
<td>$27.50</td>
<td>$53.0K</td>
<td>2.1K</td>
<td align="right">9</td>
</tr>
</tbody>
</table>
</p>
<h3>About Pinterest</h3>
<p>Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.</p>
<p>Having examined the options trading patterns of Pinterest, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Pinterest</h3>
<ul>
<li>With a volume of 24,914,740, the price of PINS is up 13.5% at $33.16. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What The Experts Say On Pinterest</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $40.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Pinterest, which currently sits at a price target of $36.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Pinterest, targeting a price of $41.<br />
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Pinterest, which currently sits at a price target of $45.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Pinterest with a target price of $38.<br />
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for Pinterest, targeting a price of $40. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pinterest with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


PINS

Pinterest Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Roku</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ROKU, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 24 uncommon options trades for Roku.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 75% bullish and 16%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $161,691, and 21 are calls, for a total amount of $1,356,914.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $100.0 for Roku, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Roku's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Roku's whale activity within a strike price range from $50.0 to $100.0 in the last 30 days. </p>
<h3>Roku Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076468_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$60.00</td>
<td>$164.7K</td>
<td>1.6K</td>
<td align="right">923</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.45</td>
<td>$24.4</td>
<td>$24.4</td>
<td>$50.00</td>
<td>$122.0K</td>
<td>1.2K</td>
<td align="right">52</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.6</td>
<td>$6.1</td>
<td>$6.6</td>
<td>$60.00</td>
<td>$118.8K</td>
<td>1.6K</td>
<td align="right">678</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$18.35</td>
<td>$17.7</td>
<td>$18.05</td>
<td>$60.00</td>
<td>$90.2K</td>
<td>122</td>
<td align="right">50</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$18.35</td>
<td>$17.7</td>
<td>$18.05</td>
<td>$60.00</td>
<td>$90.2K</td>
<td>122</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Roku</h3>
<p>Roku enables consumers to stream television programming. It has more than 90 million streaming households and provided 127 billion streaming hours in 2024. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.</p>
<h3>Present Market Standing of Roku</h3>
<ul>
<li>Trading volume stands at 6,136,047, with ROKU's price up by 13.19%, positioned at $68.97.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 80 days.</li>
</ul>
<h3>What The Experts Say On Roku</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $97.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Benchmark has revised its rating downward to Buy, adjusting the price target to $130.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Roku, targeting a price of $100.<br />
&#x2A; An analyst from Loop Capital persists with their Hold rating on Roku, maintaining a target price of $80.<br />
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $95.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Roku, targeting a price of $80. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Roku with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


ROKU

Decoding Roku's Options Activity: What's the Big Picture?

<p>Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated PPG Indus and provided 12-month price targets. The average target is $119.73, accompanied by a high estimate of $140.00 and a low estimate of $105.00. A decline of 5.18% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076456_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive PPG Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$113.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Frank Mitsch</td>
<td>Fermium Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$111.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$126.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$113.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PPG Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PPG Indus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for PPG Indus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into PPG Indus's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PPG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on PPG Indus analyst ratings.</strong></a></p>
<h2>Discovering PPG Indus: A Closer Look</h2>
<p>PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.</p>
<h3>Key Indicators: PPG Indus's Financial Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> PPG Indus's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-4.29%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> PPG Indus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.12%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.44%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> PPG Indus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.84%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> PPG Indus's debt-to-equity ratio surpasses industry norms, standing at <strong>1.13</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For PPG Indus's Future

<p>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Dick's Sporting Goods and provided 12-month price targets. The average target is $224.62, accompanied by a high estimate of $273.00 and a low estimate of $171.00. Observing a downward trend, the current average is 6.11% lower than the prior average price target of $239.23. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076448_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Dick's Sporting Goods. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$223.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$171.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$192.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$195.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$273.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$226.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dick's Sporting Goods. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dick's Sporting Goods compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Dick's Sporting Goods's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dick's Sporting Goods's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Dick's Sporting Goods analyst ratings.</strong></a></p>
<h2>All You Need to Know About Dick's Sporting Goods</h2>
<p>Dick's Sporting Goods retails athletic apparel, footwear, and equipment for sports. Dick's operates digital platforms, about 720 stores under its namesake brand (including outlet stores and House of Sport), and about 130 specialty stores under the Golf Galaxy and other nameplates. Dick's carries private-label merchandise and national brands such as Nike, The North Face, Under Armour, Callaway Golf, and TaylorMade. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.</p>
<h3>Dick's Sporting Goods's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Dick's Sporting Goods's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.45%</strong> as of 31 January, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dick's Sporting Goods's net margin excels beyond industry benchmarks, reaching <strong>7.7%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Dick's Sporting Goods's ROE excels beyond industry benchmarks, reaching <strong>9.58%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dick's Sporting Goods's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.87%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.4</strong>, Dick's Sporting Goods faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 13 Analysts Discuss Dick's Sporting Goods Stock

<p>Across the recent three months, 16 analysts have shared their insights on Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1031.19, with a high estimate of $1200.00 and a low estimate of $834.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.78%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076439_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Equinix is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$986.00</td>
<td>$990.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$990.00</td>
<td>$970.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Erik Rasmussen</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1030.00</td>
</tr>
<tr>
<td>Michael Elias</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1018.00</td>
<td>$978.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1030.00</td>
<td>$1040.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$970.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1053.00</td>
<td>$1094.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$834.00</td>
<td>$822.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$990.00</td>
<td>$1028.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$1040.00</td>
<td>$1033.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1033.00</td>
<td>$1114.00</td>
</tr>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1065.00</td>
<td>$1085.00</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1065.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equinix. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equinix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Equinix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Equinix's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Equinix analyst ratings.</strong></a></p>
<h2>Get to Know Equinix Better</h2>
<p>Equinix operates 260 data centers in 71 markets worldwide. It generates 44% of total revenue in the Americas, 35% in Europe, the Middle East, and Africa, and 21% in Asia-Pacific. The firm has more than 10,000 customers, including 2,100 network providers, that are dispersed over five verticals: cloud and IT services, content providers, network and mobile services, financial services, and enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from interconnection. Equinix operates as a real estate investment trust.</p>
<h3>Financial Insights: Equinix</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Equinix's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>4.61%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Equinix's net margin excels beyond industry benchmarks, reaching <strong>15.42%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Equinix's ROE excels beyond industry benchmarks, reaching <strong>2.5%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.41</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EQIX

What 16 Analyst Ratings Have To Say About Equinix

<p><strong>Zoetis's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) short percent of float has risen 21.39% since its last report. The company recently reported that it has <strong>9.33 million shares sold short</strong>, which is 2.1% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.49 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Zoetis Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747076431_0_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Zoetis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Zoetis's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zoetis's peer group average for short interest as a percentage of float is 3.49%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

DiaMedica Therapeutics

뉴스

에 대한 최신 뉴스 DiaMedica Therapeutics (NASDAQ:DMAC) 주식

뉴스

파트너 / 기고자

벤징가 글로벌